Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label elranatamab in high-risk smoldering multiple myeloma
NL-OMON59948Phase 2Active, not recruiting
- Sponsor
- European Myeloma Network B.V.
- Start
- Apr 2024
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of elranatamab in smoldering multiple myeloma (SMM), sponsored by European Myeloma Network B.V. Primary endpoints: Complete remission rate at the end of cycle 6 and Rate of grade 3-4 non-hematologic adverse events. Started Apr 2024; status: active, not recruiting.
02
Drugs
elranatamab
03
Conditions
smoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NL-OMON59948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59948.